Cargando…
Gene therapy avenues and COVID-19 vaccines
2020 has witnessed unprecedented situations due to coronavirus pandemic that affected all aspects of life. The whole globe lived months of uncertainty before two companies have announced the incredible results of phase III clinical trials for two different mRNA-based vaccines.
Autor principal: | Abu Abed, Omar S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170448/ https://www.ncbi.nlm.nih.gov/pubmed/34079091 http://dx.doi.org/10.1038/s41435-021-00136-6 |
Ejemplares similares
-
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena
por: Chavda, Vivek P., et al.
Publicado: (2022) -
Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues…
por: Sharma, Ridhima, et al.
Publicado: (2021) -
Refugee access to COVID-19 vaccines in Lebanon
por: Jawad, Nadine K, et al.
Publicado: (2021) -
Can influenza vaccine modify COVID-19 clinical course?
por: Eldanasory, Omar Abdelhay, et al.
Publicado: (2020) -
Reduced COVID-19 Vaccine Response in Patients Treated with Biologic Therapies for Asthma
por: Runnstrom, Martin C., et al.
Publicado: (2022)